Omkar Pharmachem Limited has submitted a regulatory filing to BSE Limited. The disclosure is made pursuant to SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026. The circular mandates the opening of a special window for the transfer and dematerialization (demat) of physical shares.
The company has enclosed copies of the newspaper advertisements published in compliance with the SEBI circular. One advertisement is in a vernacular language and one is in the English language.
The letter is signed by Bhawani S Goyal, Managing Director (DIN: 03255804), on behalf of Omkar Pharmachem Limited. The company's registered address is Ward No-03, Nangal Chaudkhry, Narnaul, Mahendragarh, Haryana-123023.
The document contains a significant amount of extraneous, unstructured, and seemingly unrelated text and data snippets interspersed with the core disclosure. This includes:
- Fragments of legal notices mentioning amounts like ₹12,73,165.38, ₹6,14,184.103, ₹5,00,040.413, ₹8,70,652.132, ₹9,67,584.549, ₹5,70,196.519, and ₹922,791.376, with dates around 18-05-2026 and 17-11-2026.
- A lengthy section in Gujarati discussing a sharp decline in gold and silver prices, drawing comparisons to the 1980s crash, and mentioning the Indian Rupee strengthening by 49 paise against the US Dollar to 92.81.
- References to non-performing assets (NPAs) of NBFCs, loan recovery processes, and asset reconstruction.
- A legal notice in Hindi referencing a case under Sections 88, 188 of the R.T. Act, with a hearing scheduled for 26.11.2026.
- News snippets about increased crude oil imports and costs for India, potential IPOs in December 2026 aiming to raise ₹10,000-12,000 crore, and a police search at the residence of a former DMK minister in Tamil Nadu.
- Miscellaneous addresses, contact details, and other fragmented information.
The purpose of the filing is solely to notify the exchange of the advertisement publication for the physical share demat window. The financial and other operational impacts of the extraneous text are not related to Omkar Pharmachem's disclosure and are not quantified or explained in the context of this filing.